Search - tctmd.com

Displaying 241 - 260 of 334

Sort: Relevancy | Date

Presentation TCT 2016

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Presenter: A. Michael Lincoff, Franz-Josef Neumann, John A. Bittl

October 30, 2016

Presentation TCT 2016

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

Presentation

Efficacy and Safety of DAPT After Complex PCI

Presenter: Gennaro Giustino

September 01, 2016

Presentation

Impact Of Gender on 2-Year Clinical Outcomes in Patients Treated With 6- or 24-Month DAPT

Presenter: Giuseppe Gargiulo

August 19, 2016

Presentation

Use of DAPT and Patient Outcomes in Those Undergoing PCI: The ROCKET AF Trial

Presenter: Matthew W. Sherwood

August 16, 2016

Presentation CCVVC 2016

Timing of DAPT Interruption and DES Thrombosis

Presenter: Usman Baber

June 16, 2016

Presentation CCVVC 2016

Optimal Duration of DAPT: Update on DAPT Guidelines

Presenter: Roxana Mehran

June 16, 2016

Presentation CCVVC 2016

Novel Anti-thrombotics in Patients with Peripheral Artery Disease

Presenter: Marc P. Bonaca

June 15, 2016

Presentation EuroPCR 2016

Effect of DAPT Termination at 12 Months on Very Late scaffold thrombosis in regular clinical practice: Data of a regional collaboration

Presenter: Robert-Jan van Geuns

May 18, 2016

Presentation Fellows 2016

Case 1: Dilemmas in DAPT and PCI Pharmacology

Presenter: Allen Jeremias

April 15, 2016

Presentation JIM 2016

DES safety and DAPT: The Ultimaster DES

Presenter: Corrado Tamburino

February 10, 2016

Presentation JIM 2016

BioFreedom DCS With 1-Month DAPT: The New Standard For High Bleeding Risk Patients

Presenter: Antonio L. Bartorelli

February 10, 2016

Presentation

Outcomes of Patients With Acute MI Undergoing PCI Receiving an Oral Anticoagulant and DAPT

Presenter: Larry R. Jackson

December 21, 2015

Presentation TCT 2015

Identifying and Studying Data Gaps: DAPT Duration What's Settled, and What's Not?

Presenter: Deepak L. Bhatt, Martin Rose, John A. Bittl

October 14, 2015

Presentation TCT 2015

Optimal DAPT Duration After DES

Presenter: George D. Dangas, Paul A. Gurbel, Somjot S. Brar

October 13, 2015

Presentation TCT 2015

Acute DAPT Decisions: Agent Selection and Whether to Load

Presenter: George D. Dangas, Paul A. Gurbel

October 13, 2015

Presentation TCT 2015

I Dont Believe DAPT Should Be Discontinued at or Before 12 Months After Elective DES Implantation!

Presenter: Eric R. Bates, Spencer B. King III, Daniel I. Simon

October 13, 2015

Advertisement

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Efficacy and Safety of DAPT After Complex PCI

Impact Of Gender on 2-Year Clinical Outcomes in Patients Treated With 6- or 24-Month DAPT

Use of DAPT and Patient Outcomes in Those Undergoing PCI: The ROCKET AF Trial

Timing of DAPT Interruption and DES Thrombosis

Optimal Duration of DAPT: Update on DAPT Guidelines

Novel Anti-thrombotics in Patients with Peripheral Artery Disease

Effect of DAPT Termination at 12 Months on Very Late scaffold thrombosis in regular clinical practice: Data of a regional collaboration

Case 1: Dilemmas in DAPT and PCI Pharmacology

DES safety and DAPT: The Ultimaster DES

BioFreedom DCS With 1-Month DAPT: The New Standard For High Bleeding Risk Patients

Outcomes of Patients With Acute MI Undergoing PCI Receiving an Oral Anticoagulant and DAPT

Identifying and Studying Data Gaps: DAPT Duration What's Settled, and What's Not?

Optimal DAPT Duration After DES

Acute DAPT Decisions: Agent Selection and Whether to Load

I Dont Believe DAPT Should Be Discontinued at or Before 12 Months After Elective DES Implantation!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content